Here are the 10-Q quarterly reports from Windtree Therapeutics New (WINT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow WINT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WINT filings page.
Windtree Therapeutics (WINT) reported a net loss of $28,085 for the quarter and $42,761 for the nine months ended September 30, 2025, driven largely by a $16,130 impairment of intangible assets. Operating expenses rose sharply to $19,882 in the quarter, reflecting that write-down, while research and development and general and administrative spending remained significant.
Cash and cash equivalents were $204 at quarter end against total liabilities of $27,584 and negative stockholders’ equity of $(11,610), underscoring heavy leverage and dependence on external financing, including convertible notes and an ELOC commitment note.
The company adopted a new strategy to generate revenue via acquisitions of small companies with FDA-approved products and entered manufacturing arrangements, while continuing its cardiovascular pipeline with partner Lee’s. It terminated the SEISMiC C cardiogenic shock trial and, after being delisted from Nasdaq in August 2025, now trades on the OTC market.
Windtree Therapeutics, Inc. (WINT) reported continued operating losses and material financing activity in the quarter. The company recorded net losses of $10.6 million and $14.7 million for the three and six months ended June 30, 2025, compared with net losses of $12.0 million and $1.8 million in the comparable 2024 periods. As of June 30, 2025, Windtree had an accumulated deficit of $861.3 million and expects to incur losses for the foreseeable future.
Management disclosed multiple financing transactions including an equity line of credit (ELOC) up to $35 million under which the company sold 0.7 million shares for net proceeds of $0.4 million during the quarter and subsequently sold 16.8 million shares for net proceeds of $10.1 million. The company raised proceeds from convertible note financings and warrants that produced a $7.3 million loss on debt issuance and a $0.8 million fair-value adjustment recorded in other income (expense). Management stated it does not have sufficient cash and cash equivalents at the report date to support operations for the next 12 months and that these conditions raise substantial doubt about the company’s ability to continue as a going concern.